SAM
MLYS icon

Smartleaf Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Smartleaf Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.5K Buy
1,639
+636
+63% +$18.7K ﹤0.01% 1601
2025
Q4 		$35.6K Sell
1,003
-14
-1% -$561 ﹤0.01% 1715
2025
Q3 		$40K Buy
1,017
+676
+198% +$14.6K ﹤0.01% 1497
2025
Q2 		$4.67K Sell
341
-583
-63% -$8.45K ﹤0.01% 2079
2025
Q1 		$13.5K Sell
924
-981
-51% -$11.3K ﹤0.01% 1797
2024
Q4 		$23.9K Buy
1,905
+368
+24% +$4.81K ﹤0.01% 1545
2024
Q3 		$18.3K Buy
1,537
+1,180
+331% +$14.3K ﹤0.01% 1393
2024
Q2 		$4.11K Buy
+357
New +$4.5K ﹤0.01% 1893

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Smartleaf Asset Management's MLYS Position: Q1 2026 in Review

Smartleaf Asset Management increased its Mineralys Therapeutics (MLYS) stake by 63% in Q1 2026, buying an estimated $18.7K and bringing the position to 1,639 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1601.

Smartleaf Asset Management first reported a position in MLYS in Q2 2024 and has held it in 8 quarters since. The position peaked at $40K in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Smartleaf Asset Management held 1,639 shares of Mineralys Therapeutics worth $38.5K as of Q1 2026.
  • Smartleaf Asset Management bought 636 Mineralys Therapeutics shares in Q1 2026, an estimated $18.7K.
  • Mineralys Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1601 holding.
  • Smartleaf Asset Management first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Smartleaf Asset Management's Mineralys Therapeutics position peaked at $40K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.